MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells

Molecular Pharmaceutics

Volumn 7, Issue 5, 2010, Pages 1576-1584

  Zhang, Tao ^a   Li, Yanyan ^a   Zhu, Zhenkun ^a   Gu, Mancang ^a   Newman, Bryan ^a   Sun, Duxin ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

17 AAG; ERK; Hsp90; MEK

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN E; HEAT SHOCK PROTEIN 90; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; TANESPIMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MIGRATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; BUTADIENES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG SYNERGISM; ENZYME ACTIVATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; KINETICS; LACTAMS, MACROCYCLIC; MAP KINASE SIGNALING SYSTEM; NITRILES; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 77957724510     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900321a     Document Type: Article

References (45)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007 CA-Cancer J. Clin. 2007, 57 (1) 43-66
2. Gronborg, M.; Kristiansen, T. Z.; Iwahori, A.; Chang, R.; Reddy, R.; Sato, N.; Molina, H.; Jensen, O. N.; Hruban, R. H.; Goggins, M. G.; Maitra, A.; Pandey, A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach Mol. Cell. Proteomics 2006, 5 (1) 157-71
3. Li, D.; Xie, K.; Wolff, R.; Abbruzzese, J. L. Pancreatic cancer Lancet 2004, 363 (9414) 1049-57
4. Cancer Facts & Figures 2009. America Cancer Society.
5. Ahrendt, S. A.; Pitt, H. A. Surgical management of pancreatic cancer Oncology (Williston Park) 2002, 16 (6) 725-34; discussion 734, 736-8, 740, 743
6. Xiong, H. Q. Molecular targeting therapy for pancreatic cancer Cancer Chemother. Pharmacol. 2004, 54 (1) S69-77
7. Lai, B. T.; Chin, N. W.; Stanek, A. E.; Keh, W.; Lanks, K. W. Quantitation and intracellular localization of the 85K heat shock protein by using monoclonal and polyclonal antibodies Mol. Cell. Biol. 1984, 4 (12) 2802-10
8. Roe, S. M.; Ali, M. M.; Meyer, P.; Vaughan, C. K.; Panaretou, B.; Piper, P. W.; Prodromou, C.; Pearl, L. H. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37) Cell 2004, 116 (1) 87-98
9. Whitesell, L.; Lindquist, S. L. HSP90 and the chaperoning of cancer Nat. Rev. Cancer 2005, 5 (10) 761-72
10. Chiosis, G.; Neckers, L. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive ACS Chem. Biol. 2006, 1 (5) 279-84
11. Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation Trends Mol. Med. 2004, 10 (6) 283-90
12. Messaoudi, S.; Peyrat, J. F.; Brion, J. D.; Alami, M. Recent advances in Hsp90 inhibitors as antitumor agents Anticancer Agents Med. Chem. 2008, 8 (7) 761-82
13. Usmani, S. Z.; Bona, R.; Li, Z. 17 AAG for HSP90 inhibition in cancer - from bench to bedside Curr. Mol. Med. 2009, 9 (5) 654-64
14. Price, J. T.; Quinn, J. M.; Sims, N. A.; Vieusseux, J.; Waldeck, K.; Docherty, S. E.; Myers, D.; Nakamura, A.; Waltham, M. C.; Gillespie, M. T.; Thompson, E. W. The heat shock protein 90 inhibitor, 17-allylamino-17- demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line Cancer Res. 2005, 65 (11) 4929-38
15. Yano, A.; Tsutsumi, S.; Soga, S.; Lee, M. J.; Trepel, J.; Osada, H.; Neckers, L. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (40) 15541-6
16. Favata, M. F.; Horiuchi, K. Y.; Manos, E. J.; Daulerio, A. J.; Stradley, D. A.; Feeser, W. S.; Van Dyk, D. E.; Pitts, W. J.; Earl, R. A.; Hobbs, F.; Copeland, R. A.; Magolda, R. L.; Scherle, P. A.; Trzaskos, J. M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase J. Biol. Chem. 1998, 273 (29) 18623-32
17. Koga, F.; Xu, W.; Karpova, T. S.; McNally, J. G.; Baron, R.; Neckers, L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (30) 11318-22
18. Wallace, E. M.; Lyssikatos, J. P.; Yeh, T.; Winkler, J. D.; Koch, K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy Curr. Top. Med. Chem. 2005, 5 (2) 215-29
19. Hoadley, K. A.; Weigman, V. J.; Fan, C.; Sawyer, L. R.; He, X.; Troester, M. A.; Sartor, C. I.; Rieger-House, T.; Bernard, P. S.; Carey, L. A.; Perou, C. M. EGFR associated expression profiles vary with breast tumor subtype BMC Genomics 2007, 8, 258
20. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009 CA-Cancer J. Clin. 2009, 59 (4) 225-49
21. Evans, D. B.; Abbruzzese, J. L.; Rich, T. R. Cancer of the pancreas. In Cancer: Principles and Practice of Oncology; De Vita, V. T.; Hellman, S.; Rosenberg, S. A., Eds.; 1997; pp 1054 - 87.
22. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress Ann. N.Y. Acad. Sci. 2007, 1113, 202-16
23. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc. Natl. Acad. Sci. U.S.A. 1994, 91 (18) 8324-8
24. Supko, J. G.; Hickman, R. L.; Grever, M. R.; Malspeis, L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent Cancer Chemother. Pharmacol. 1995, 36, 305-15
25. Banerji, U.; O'Donnell, A.; Scurr, M.; Pacey, S.; Stapleton, S.; Asad, Y.; Simmons, L.; Maloney, A.; Raynaud, F.; Campbell, M.; Walton, M.; Lakhani, S.; Kaye, S.; Workman, P.; Judson, I. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J. Clin. Oncol. 2005, 23 (18) 4152-61
26. Goetz, M. P.; Toft, D.; Reid, J.; Ames, M.; Stensgard, B.; Safgren, S.; Adjei, A. A.; Sloan, J.; Atherton, P.; Vasile, V.; Salazaar, S.; Adjei, A.; Croghan, G.; Erlichman, C. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer J. Clin. Oncol. 2005, 23 (6) 1078-87
27. Premkumar, D. R.; Arnold, B.; Jane, E. P.; Pollack, I. F. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells Mol. Carcinog. 2006, 45 (1) 47-59
28. Premkumar, D. R.; Arnold, B.; Pollack, I. F. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth Mol. Carcinog. 2006, 45 (5) 288-301
29. Sain, N.; Krishnan, B.; Ormerod, M. G.; De Rienzo, A.; Liu, W. M.; Kaye, S. B.; Workman, P.; Jackman, A. L. Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT Mol. Cancer Ther. 2006, 5 (5) 1197-208
30. Cao, X.; Bloomston, M.; Zhang, T.; Frankel, W. L.; Jia, G.; Wang, B.; Hall, N. C.; Koch, R. M.; Cheng, H.; Knopp, M. V.; Sun, D. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor Clin. Cancer Res. 2008, 14 (6) 1831-9
31. Jane, E. P.; Pollack, I. F. The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells Cancer Lett. 2008, 268 (1) 46-55
32. Roforth, M. M.; Tan, C. Combination of rapamycin and 17-allylamino-17- demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells Anticancer Drugs 2008, 19 (7) 681-8
33. Galabova-Kovacs, G.; Kolbus, A.; Matzen, D.; Meissl, K.; Piazzolla, D.; Rubiolo, C.; Steinitz, K.; Baccarini, M. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts Cell Cycle 2006, 5 (14) 1514-8
34. Friday, B. B.; Adjei, A. A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin. Cancer Res. 2008, 14 (2) 342-6
35. Dhillon, A. S.; Hagan, S.; Rath, O.; Kolch, W. MAP kinase signalling pathways in cancer Oncogene 2007, 26 (22) 3279-90
36. Ramos, J. W. The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells Int. J. Biochem. Cell Biol. 2008, 40 (12) 2707-19
37. Greulich, H.; Erikson, R. L. An analysis of Mek1 signaling in cell proliferation and transformation J. Biol. Chem. 1998, 273 (21) 13280-8
38. Cheng, M.; Sexl, V.; Sherr, C. J.; Roussel, M. F. Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1) Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (3) 1091-6
39. Tachibana, K.; Machida, T.; Nomura, Y.; Kishimoto, T. MAP kinase links the fertilization signal transduction pathway to the G1/S-phase transition in starfish eggs EMBO J. 1997, 16 (14) 4333-9
40. Lapenna, S.; Giordano, A. Cell cycle kinases as therapeutic targets for cancer Nat. Rev. Drug Discovery 2009, 8 (7) 547-66
41. Masaki, T.; Shiratori, Y.; Rengifo, W.; Igarashi, K.; Yamagata, M.; Kurokohchi, K.; Uchida, N.; Miyauchi, Y.; Yoshiji, H.; Watanabe, S.; Omata, M.; Kuriyama, S. Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis Hepatology 2003, 37 (3) 534-43
42. Larrea, M. D.; Wander, S. A.; Slingerland, J. M. p27 as Jekyll and Hyde: regulation of cell cycle and cell motility Cell Cycle 2009, 8 (21) 3455-61
43. Klemke, R. L.; Cai, S.; Giannini, A. L.; Gallagher, P. J.; de Lanerolle, P.; Cheresh, D. A. Regulation of cell motility by mitogen-activated protein kinase J. Cell Biol. 1997, 137 (2) 481-92
44. Honma, N.; Genda, T.; Matsuda, Y.; Yamagiwa, S.; Takamura, M.; Ichida, T.; Aoyagi, Y. MEK/ERK signaling is a critical mediator for integrin-induced cell scattering in highly metastatic hepatocellular carcinoma cells Lab Invest. 2006, 86 (7) 687-96
45. Takino, T.; Miyamori, H.; Watanabe, Y.; Yoshioka, K.; Seiki, M.; Sato, H. Membrane type 1 matrix metalloproteinase regulates collagen-dependent mitogen-activated protein/extracellular signal-related kinase activation and cell migration Cancer Res. 2004, 64 (3) 1044-9